Understanding how SARS-CoV-2 uses specific proteins to infect cells
How infectious SARS-CoV-2 exploits two ER membrane proteins to promote infection
This study looks at how the COVID-19 virus uses certain proteins in our cells to help it spread, and by understanding this process, researchers hope to find better treatments for patients with COVID-19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11109423 on NIH RePORTER |
What this research studies
This research investigates how the SARS-CoV-2 virus hijacks two specific proteins in the endoplasmic reticulum of human cells to enhance its ability to replicate and spread. By studying these proteins, RTN3 and SigmaR1, the researchers aim to uncover the mechanisms that allow the virus to exploit these cellular factors. The findings could provide crucial insights into the virus's infection process and help in the development of new antiviral treatments. Patients may benefit from this research as it could lead to more effective therapies against COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by COVID-19 or those at high risk of severe illness from the virus.
Not a fit: Patients who are not infected with SARS-CoV-2 or who have already recovered from COVID-19 may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiviral drugs that effectively combat SARS-CoV-2 infection.
How similar studies have performed: Previous research has shown success in targeting viral mechanisms for treatment, suggesting that this approach could also yield valuable results.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Tsai, Billy — University of Michigan at Ann Arbor
- Study coordinator: Tsai, Billy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.